Videos

Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-versus-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.

An expert discusses how pharmacists can identify high-risk patients for pneumococcal disease by reviewing medication profiles for immunosuppressants and using electronic medical record vaccine tracking tools, while emphasizing that vulnerable populations face higher morbidity, mortality, and hospitalization rates compared with healthy individuals.

Panelists discuss how the use of both clinician- and patient-reported scales—such as the Impact TD scale, TDIS, and Impact TD Pro—enhances understanding of tardive dyskinesia’s true impact on daily functioning and quality of life, emphasizing the importance of incorporating patient perspectives to guide early, personalized treatment strategies that improve physical symptoms and overall well-being.

Panelists discuss how tardive dyskinesia in older adults often goes unrecognized due to symptom overlap with normal aging, underscoring the importance of early screening, timely intervention with evidence-based treatments like VMAT2 inhibitors, and a multidisciplinary approach to preserve function, independence, and mental well-being.

An expert discusses how pneumococcal disease presents differently across age groups, with children primarily experiencing ear infections, whereas adults face more serious, invasive complications such as bacteremia and meningitis, though vaccination efforts have significantly reduced overall incidence rates.

An expert discusses how different tyrosine kinase inhibitor (TKI) mechanisms of action, including asciminib’s allosteric binding vs traditional ATP-competitive inhibitors, influence treatment selection based on off-target effects and adverse effect profiles, with patients with advanced-phase chronic myeloid leukemia (CML) requiring second-generation or higher TKIs for faster response rates.

An expert discusses how National Comprehensive Cancer Network (NCCN) guidelines recommend first-line chronic myeloid leukemia (CML) treatments including imatinib, nilotinib, and newer agents, emphasizing the importance of close monitoring through weekly laboratory tests and quantitative polymerase chain reaction (PCR) to track BCR::ABL1 transcript levels and ensure patients meet critical milestones at 3, 6, and 12 months.

Shaji Kumar, MD, shares data and insights from the phase 2 RedirecTT-1 study.

Megan Ehret, PharmD, MS, BCPP, FAAPP, discusses the clinical benefits of long-acting injectables for treating alcohol use disorder and psychiatric conditions, highlighting the pharmacist’s role in improving adherence, addressing stigma, and expanding access to care.

Pharmacy experts share the benefits of the annual Oncology Pharmacists Connect meeting.

Gowri Reddy Rocco, MD, MS, reveals that repairing gut health through targeted nutrition is essential for combating long COVID and preventing autoimmune complications.

Kevin Chen, PharmD, MS, BCOP, CPP highlighted key thoracic cancer advances from the 2025 ASCO Annual Meeting.

Scott Soefje, PharmD, MBA, BCOP, shares insights about the evolving role of pharmacists at the 2025 OPC meeting.

Gabe Hinojosa, PharmD, BCOP, shares key data for pharmacists from the 2025 American Society of Clinical Oncology Annual Meeting.

Manish Agrawal, MD, explores the evolving role of pharmacists in psychedelic-assisted therapy, highlighting ongoing efforts to develop standardized protocols and the emerging involvement of pharmacy teams in patient education and safety.

Continuous glucose monitoring (CGM) is poised to transform type 2 diabetes management.

Ready-to-use glucagon simplifies hypoglycemia rescue by providing easy-to-use options for patients and caregivers.

Manish Agrawal, MD, discusses the expanding influence of his group-based psychedelic therapy model in oncology and beyond, highlighting its adaptation in military post-traumatic stress disorder (PTSD) research, the sustained benefits of long-term patient integration, and growing institutional interest in psychedelic-assisted therapy.

Panelists discuss how the progression of undiagnosed or untreated tardive dyskinesia in older adults can severely compromise independence and quality of life, emphasizing the need for early recognition, risk factor management, and a multidisciplinary approach—including pharmacists—to ensure timely, individualized, and balanced treatment.

Panelists discuss how enhancing the management of tardive dyskinesia in older patients involves recognizing subtle clinical signs, addressing mental health stigma, and leveraging the pivotal role of pharmacists in early detection, patient education, and coordinated, compassionate care.

Continuous glucose monitors provide individuals with type 2 diabetes with real-time, actionable insights about their health.

Experts discuss the low prescription rates of ready-to-use glucagon for individuals with diabetes.

Expert shares insights on advancing diabetes care in community pharmacies.

The expert discusses the evolving landscape of diabetes treatment, emphasizing the importance of comprehensive care beyond glucose management.

Heidi Finnes, PharmD, BCOP, FHOPA, discusses the evolving landscape of treatment of cutaneous malignancies.

Jolynn Sessions, PharmD, BCOP, FHOPA, shares her experience as a clinical pharmacist and the value of the Oncology Pharmacists Connect meeting.

Amy Duong, PharmD, BCACP, highlights the importance of patient counseling and addressing logistical challenges in treating patients with chronic inflammatory demyelinating neuropathy (CIDP).

Gowri Reddy Rocco, MD, MS, discusses how low vitamin D3 levels, insulin resistance, and metabolic health are critical yet often overlooked factors in understanding and treating long COVID.

Expert shares key upcoming sessions at the American Diabetes Association 85th Scientific Sessions.

Panelists discuss how advancing chronic graft-vs-host disease (cGVHD) management involves improving steroid response rates, exploring combination therapies, utilizing biomarkers for personalized treatment, and striving for steroid-free first-line options to enhance patient outcomes and reduce long-term adverse effects.